Immune to Cancer: The CRI Blog
-
ASCO 2016 Update: The Personal Side of Immunotherapy
To help more patients, treatments must get personal.
-
Inmunoterapia vs. Quimioterapia: ¿Cual es la diferencia?
Respondemos las preguntas frecuentes de los pacientes sobre las diferencias entre la inmunoterapia y la quimioterapia, incluidos…
-
ASCO 2016: The Year of Immunotherapy
Chicago hosts top clinical cancer conference, immunotherapy shines.
-
The Evolution of Cancer Treatment: From Simplistic Strategies to Personalized Prescriptions
Immunotherapy, personalized medicine poised to revolutionize cancer treatment.
-
Author Shares Her Immunotherapy Experience in New Memoir
In her new memoir, Mary Elizabeth Williams documents her experience with metastatic melanoma, and her subsequent treatment…
-
Immunotherapy in the Spotlight
Dateline NBC took a closer look at this revolution known as immunotherapy and plans to tap into…
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.
-
Cancer Research Institute Raises $1.2 Million at Annual Through the Kitchen
On Sunday, May 16, 2016, the Cancer Research Institute (CRI) held its 34th annual “Through the Kitchen”…
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.